



# **D8.1 – D1.3.2 Synergies Working Group Establishment WP8**



**Co-funded by  
the European Union**

Funded by the European Union under the Horizon Europe Framework Programme. Grant Agreement N°: 101095426.

## Technical References

<b>Deliverable No.</b>	<b>D8.1 (D1.3.2)</b>
<b>Dissemination Level<sup>1</sup></b>	PU
<b>Work Package</b>	8
<b>Lead beneficiary</b>	FICYT
<b>Version</b>	3
<b>Due date of deliverable</b>	30 April 2023
<b>Actual submission date</b>	18 May 2023

## Versions

<b>Version</b>	<b>Person</b>	<b>Partner</b>	<b>Date</b>
1	María Escribano, María González, Inés Rey	FICYT	21 April 2023
2	María Escribano, María González, Inés Rey	FICYT	12 May 2023
3	María Escribano, María González, Inés Rey	FICYT	17 May 2023

**Approved by Coordinator on:** 18/05/2023

**Disclaimer.** Funded by the European Union under the Horizon Europe Framework Programme. Grant Agreement N<sup>o</sup>: 101095426. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or European Health and Digital Executive Agency (HADEA). Neither the European Union nor the granting authority can be held responsible for them

---

<sup>1</sup> PU = Public  
SEN = Sensitive

## D8.1 – D1.3.2 Synergies Working Group Establishment

### Table of contents

GLOSSARY / LIST OF ACRONYMS .....	3
EXECUTIVE SUMMARY .....	6
1. PURPOSE AND OBJECTIVES.....	8
2. METHODOLOGY .....	11
3. RESULTS .....	12
4. CONCLUSIONS.....	55
5. ANNEXES.....	58

## GLOSSARY / LIST OF ACRONYMS

AWP: Annual Work Plan

B1MG: Beyond 1 Million Genomes Project

BBMRI: Biobanking and Biomolecular Resources Research Infrastructure

BE READY: Building a European strategic REsearch and innovation Area in Direct sYnergy with EU and International Initiatives for Pandemic Preparedness

Col: Conflict of Interest

COMET: Core Outcome Measures in Effectiveness Trials

conect4children: Collaborative Network for European Clinical Trials for Children

CSA IC2PerMed: Integrating China in the International Consortium for Personalised Medicine

CSA SINO-EU PerMed: Cooperation between China and Europe in Personalised Medicine

CTTI: Clinical Trials Transformation Initiative

E4H: ERA4Health

EATRIS: European Infrastructure for Translational Medicine

ECRAID: European Clinical Research Alliance on Infectious Diseases

ECRIN: European Clinical Research Infrastructure Network

EDCTP: European & Developing Countries Clinical Trials Partnership

EIT Health-KIC: European Institute of Innovation and Technology Health - Knowledge and Innovation Community

EJP RD: European Joint Programme on Rare Diseases

ELIXIR: Life-Science Infrastructure for Biological Information

EMA: European Medicines Agency

EP PerMed: European Partnership for Personalised Medicine

EOSC: European Open Science Cloud

ERA: European Research Area

ERA PerMed: ERA-Net Cofund on Personalised Medicine

ERA-Net Neuron: European Research Area Network of European Funding for Neurosciences Research

ERDF: European Regional Development Fund

ERINHA: European Research Infrastructure on Highly Pathogenic Agents  
ESFRI: European Strategy Forum on Research Infrastructures  
ESF+: European Social Fund Plus  
EU: European Union  
EU4Health Programme: European Union for Health Programme  
EUHA: European University Hospital Alliance  
EUP AH&W: EU Partnership Animal Health and Welfare  
EU-Africa PerMed Project: Building links between Europe and Africa in Personalised Medicine  
EU-AMRI: European Alliance of Medical Research Infrastructures  
EU-Openscreen-ERIC: Not-for-profit European Research Infrastructure Consortium (ERIC) for chemical biology and early drug discovery  
EU-PEARL: EU Patient-centric clinical trial platforms  
EuroBioimaging ERIC: European Research Infrastructure for Imaging Technologies in Biological and Biomedical Sciences  
FACCEJPI: Joint Programming Initiative on Agriculture, Food Security and Climate Change  
FutureFoodS: European Partnership for a Sustainable Future of Food Systems  
GA: Grant Agreement  
GACD: Global Alliance for Chronic Diseases  
ICPerMed: International Consortium for Personalised Medicine  
IHI: Innovative Health Initiative  
IICS: Investigator Initiated Clinical Studies  
INFRAFRONTIER: European Research Infrastructure for Modelling Human Diseases  
IRDIRC: International Rare Diseases Research Consortium  
JPI AMR: Joint Programming Initiative on Antimicrobial Resistance  
JPI HDHL: Joint Programming Initiative a Healthy Diet for a Healthy Life  
JPND Research: Joint Programme - Neurodegenerative Disease Research  
JTC: Joint Transnational Calls  
MIRRI: Microbial Resource Research Infrastructure  
NordForsk: Organisation under the Nordic Council of Ministers that facilitates and provides funding for Nordic research cooperation  
OH AMR: Candidate European Partnership One Health Antimicrobial Resistance  
PARC: Partnership for the Assessment of Risks from Chemicals  
SBEP: Sustainable Blue Economy Partnership  
SHARE ERIC: Survey of Health Ageing and Retirement in Europe  
THCS: Transforming Health Care Systems Partnership

The global health network: Platform and community of health workers and researchers

ToR: Terms of Reference

TRANSCAN: Sustained collaboration of national and regional programmes in cancer research

Trials@Home: Centre of Excellence for Decentralised Clinical Trials

SWG: Synergies Working Group

SRIA: Strategic Research and Innovation Agenda

Water4All: Partnership Water security for the planet

WP: Work Package

## EXECUTIVE SUMMARY

The **purpose** of this public deliverable is to describe the methodology followed to establish the Synergies Working Group (SWG) committed in the framework of the **Task 1.3.2 - Creation of a Synergies Working Group (SWG)**, of the WP named **WP1.3 Exploring Synergies of Pillar 1**, Work Package number **WP8**, of the Partnership ERA4Health - Fostering a European Research Area for Health Research (E4H).

The **main purpose of the action** carried out is to identify a contact person for each of the European/international initiatives identified and nominate a chair from the E4H partners for each of the categories of the initiatives.

The **objective** of the deliverable is to describe and give an overview of:

- the activities carried out to identify and select the members of the Synergies Working Group,
- the establishment of the Synergies Working Group. Afterwards, it is described the methodology followed for the creation of the SWG.

Main results:

- 59 contact persons have been identified for those initiatives.
- 59 contact persons have been contacted.
- 37 contact persons have been officially included so far as members of the SWG.
  - 19 members of the SWG in the field of Health
  - 6 members of the SWG in other fields than Health
  - 12 members of the SWG in the category of Initiatives related to Clinical Studies and Research Infrastructures.

Once the SWG has been created and the synergies with all the European initiatives have been identified, an annual workshop will be organized to bring together all the SWG members (representatives of each of the initiatives identified) and the partners of E4H to initiate a debate on the potential synergies identified. The main conclusions of this workshop will be sent to the Secretariats of E4H which will be used to ensure that no overlapping is being included in the E4H work plans and funding calls. National and regional policy makers and funding managers will be also invited to the workshop in order that they receive feedback on the existing European

initiatives related to the priority areas of E4H and help them align their national/regional policies to the existing initiatives at European and international level.

EC representatives will also be invited to attend the SWG annual workshop to aid identifying further synergies with other European initiatives and stakeholders and ensure the alignment with the Health Work Programme in Horizon Europe, especially important to avoid overlapping in the call topics.

The content of this deliverable will be updated during the whole duration of the Partnership E4H. Contact persons will continue to be sought for those initiatives that do not have an officially assigned member.



## 1. PURPOSE AND OBJECTIVES

The main objective of WP8 (Exploring Synergies) is to create synergies with other related initiatives to avoid overlap and duplication of national and EU research funding. The aim of this WP is to explore synergies between activities and topic of ERA4Health and other relevant initiatives. In order to foster a European Research Area (ERA) for Health, a close interaction of the scientific community with policy makers, R&I funding organizations, health and care systems, European programmes and other stakeholders is needed. This partnership holds a strategic position among the biomedical and health research community and relevant funding organizations. It brings together public and private research performing organisations, pre-clinical and clinical research communities. Therefore, it is particularly well suited to promote collaboration and the desired interactions at a transnational level, towards a European (and beyond) Research Area in Health Research.

E4H has worked on the identification of synergies with partnerships, programmes, infrastructures and other activities at both EU and international levels in order to work with them and ensure added value to initiatives and instruments that are ongoing.

Synergies among European/International initiatives will result in better innovation governance, more public-public and public-private cooperation and improved R&I support in the countries & regions.

For ERA4Health partnership it is crucial to connect with other key players and initiatives in the health domain and beyond to increase the impact of R&I investments on the societal challenge that it addresses. To ensure coherence and complementarity of activities and leverage knowledge and investment possibilities, the partnership as committed in the Annex I of the Grant Agreement (GA) of E4H with the European Commission, will establish collaborations with other European partnerships, clusters, mission and programmes under Horizon Europe as well as explore collaborations with other relevant activities at EU and international level.

For doing that, E4H has worked on the identification of European/international initiatives with potential synergies in terms of funding and research activity, and in the identification of contact persons for each of the initiatives identified who will help review/confirm the synergies

previously described by FICYT. These contact persons will be invited to be a member of the SWG which main role will be:

- To help define the synergies among the European/international initiatives identified, and
- Participate in an annual workshop where all the initiatives will be presented. The Secretariats and partners of E4H, national/regional policy makers, EC representatives and stakeholders will be invited to the workshop to get information on the existing initiatives and the potential synergies among them and E4H.

The **purpose** of this deliverable is to describe the methodology followed to establish the Synergies Working Group (SWG) committed in the framework of the **Task 1.3.2**, of the WP named **WP1.3 Exploring Synergies of Pillar 1**, Work Package number **WP8**, of the Partnership ERA4Health - Fostering a European Research Area for Health Research (E4H).

The **main purpose of the action** carried out is to identify a contact person for each of the European/international initiatives identified and nominate a chair from the E4H partners for each of the categories of the initiatives.

The **objective** of the deliverable is to describe and give an overview of:

- the activities carried out to create the Synergies Working Group,
- the list of the members of the Synergies Working Group

This deliverable will be disseminated as a **PUBLIC** document. Specifically, this deliverable is addressed to:

- **The Secretariats of E4H and the partners of E4H:** the information collected will be sent to the Secretariats of E4H in order that they have it into consideration for the elaboration of the annual working plans and the JTCs, to help avoid duplicities with the funding covered by other initiatives.
- **European, National and regional policy makers:** this information will be shared with as many European, National and regional policy makers as possible for them to get knowledge on the existing initiatives and help them better align the structural programmes of regional and national public administrations with other existing programmes.
- The **managers and coordinators** of all the European/international initiatives identified (and other potential ones) which contribute to avoid overlaps in the topics funded by any

of the initiatives identified and help initiate potential collaborations once knowing all the existing initiatives.

- **Other stakeholders in the fields of the Partnership, and in the field of Health in general**, who will get information about other European initiatives that may have synergies with those managed by them.
- **The whole society**: the final documents will be spread throughout the general dissemination channels of E4H and mailing lists of the partners of E4H to reach as much audience as possible.

The content of this deliverable will also feed the activities of:

- **Work Package 4** of E4H – Communication, Dissemination and Exploitation, which main aim is to raise awareness about ERA4Health objectives, activities and results and ensure the timely dissemination of its outputs to different target audiences to enhance actions by governments and stakeholders. The members of the SWG will also help contribute to disseminate the results of the deliverables D8.1 – D1.3.2 Synergies Working Group Establishment and D8.4. – D1.3.1 Portfolio of Synergies of JTC2022
- **Work Package 5** of E4H – Synergies and External Relations, which main aim is to promote synergies and actively engage with relevant stakeholders and initiatives at EU and International level within the area of ERA4Health, so to increase mutual awareness and establish an effective and efficient collaboration in order to avoid duplication of investments, work and related activities. The initiatives and contact persons identified in WP8 will be considered for the collaborations that will be initiated in the framework of WP5. Contact persons for each initiative are essential to initiate collaborations and organise common activities.
- **Work Package 15** of E4H – Synergies with other initiatives implementing clinical studies, which main aim is coordinate the funding of multinational Investigator Initiated Clinical Studies (IICSs) through the ERA4Health mechanism with all the other funding sources able to fund multinational clinical studies and identify the initiatives /organisations able to provide support in the planning, design and conduct of multinational IICS. Contact persons for each initiative are essential to initiate collaborations and organise common activities.

## 2. METHODOLOGY

The methodology followed for the creation of the SWG has followed the next steps:

- **Identification of a contact person for each initiative** identified during the elaboration of the SRIA of E4H and the JTC2022 and those new initiatives identified in Task 1.3.1.
- **Review of the list of contacts by 32 partners of E4H** (considering the updates in the E4H partners during the execution of the activities referred to in this deliverable) for them to confirm the contact persons identified and suggest contact persons for those initiatives with no contact person identified.
- **Elaboration of a new list of contacts:** this list will be used to invite the contact persons to be a member of the SWG.

The contacts have been distributed according to three categories of initiatives that are the same used for the categorisation of the initiatives considered in Task 1.3.1. There were four categories indicated in the Annex I of the GA (1- Initiatives related to E4H priority areas in the field of Health in the framework of H2020/HE, 2- Initiatives of non-E4H areas in the field of Health in the framework of H2020/HE, 3- Initiatives in non-Health fields and 4- Initiatives that support Clinical studies and Research Infrastructures), but it was found that all but one of the category 1 initiatives had ended, so categories 1 and 2 were merged to create more consistent and balanced categories. The three categories finally considered are:

- Initiatives in the field of Health
  - Initiatives in other fields than Health
  - Initiatives related to Clinical Studies and Research Infrastructure
- **Elaboration of a model of a Statement of Acceptance** (see model in Annex I) to be given to the contact persons for each European initiatives for them to authorise E4H to accept being including as a member of the SWG and use the information given by them for the justification and dissemination activities of the project and be informed of the store of their data in accordance with the provisions of Regulation (EU) 2016/679 of the European Parliament and of the Council, of 27 April 2016.

- **Elaboration of a template of Profile Form** (see model in Annex II) to be sent to the contact persons for each European initiative, in order that they provide some information about their expertise and background.
- **An e-mail was sent to all the contact persons identified** for each initiative to invite them to be part of the SWG. All those who accepted the invitation were sent the Statement of Acceptance and the Profile Form.
- **Periodic reminders** have been sent to those contact persons who did not answer.
- **Contingency measure** applied: if FICYT does not receive any answer after two reminders, a new contact person will be identified. While searching new contacts, and to avoid that any initiative does not have representation, those initiatives with no contact will be assigned to the E4H partners participating in the task 1.3.3 to help identify synergies and present the initiative in a workshop that will be organised annually.
- The list of members of the SWG will be updated periodically if new initiatives are identified throughout the execution of E4H.

### 3. RESULTS

The main results obtained after the execution of the activities described in this deliverable are directly linked to the deliverable D8.4 – List of Synergies. During the activities described in the framework of D8.4, **56 Initiatives** were identified, for which:

- **59 contact persons have been identified.**
- **59 contact persons have been contacted.**
- **37 contact persons have been officially included so far as members of the SWG.**
  - **19 members of the SWG in the field of Health**
  - **6 members of the SWG in other fields than Health**
  - **12 members of the SWG in the category of Initiatives related to Clinical Studies and Research Infrastructures**

The table 1 shows the list of contact persons for each initiative. As mentioned above, three categories will be considered:

- 1) Initiatives in the field of Health
- 2) Initiatives in other fields than Health
- 3) Initiatives related to Clinical Studies and Research Infrastructures

Table 1: List of members of the SWG

Ref*	Initiative	Contact Name	Invitation sent (date)	Acceptance (date)	Profile form / Statement of Acceptance sent (date)	Profile form / Statement of Acceptance received (date)
<b>1) INITIATIVES IN THE FIELD OF HEALTH</b>						
1.1	JPI-HDHL	Jessie Doppler	28/02/2023	28/02/2023	28/02/2023	09/03/2023
1.2	Horizon Europe Cluster 1	EC representative <sup>5</sup>	Not applicable	Not applicable	Not applicable	Not applicable
1.3	EU4Health	María José González de Suso	14/03/2023	17/04/2023	17/04/2023	27/04/2023
1.4	TRANSCAN-3	Inés Rey	10/04/2023	10/04/2023	10/04/2023	10/04/2023
1.5	ERA PerMed	Cristina Nieto	27/02/2023	08/03/2023	08/03/2023	10/04/2023
1.6	EJP RD	Daria Julkowska	28/02/2023	28/02/2023	08/03/2023	09/03/2023
1.7	JPI AMR	Laura Marin	28/02/2023	28/02/2023	08/03/2023	13/03/2023
1.8	IHI	Magali Poinot	29/03/2023	17/04/2023	17/04/2023	18/04/2023
1.9	EP PerMed	Wolfgang Ballensiefen	28/02/2023	02/03/2023	02/03/2023	29/03/2023

<sup>5</sup> EC representatives will also be invited to attend the SWG annual workshop to aid identifying further synergies with other European initiatives and stakeholders and ensure the alignment with the Health Work Programme in Horizon Europe, especially important to avoid overlapping in the call topics.

1.10	BE READY	Hervé Raoul	21/03/2023	23/03/2023	24/03/2023	30/03/2023
1.11	ERA-Net NEURON	Hella Lichtenberg	28/02/2023	16/03/2023	16/03/2023	29/03/2023
1.12	JPND	Philippe Amouyel	12/04/2023	13/04/2023	14/04/2023	02/05/2023
1.13	OH AMR	Laura Marin	28/02/2023	28/02/2023	08/03/2023	13/03/2023
1.14	ICPerMed	Wolfgang Ballensiefen	28/02/2023	02/03/2023	02/03/2023	29/03/2023
1.15	IRDIRC	Daria Julkowska	28/02/2023	28/02/2023	08/03/2023	09/03/2023
1.16	EU-Africa PerMed Project	Erika Sela	08/03/2023	08/03/2023	09/03/2023	09/03/2023
1.17	CSA IC2PerMed	Stefania Boccia	08/03/2023	08/03/2023	08/03/2023	08/03/2023
1.18	THCS	Chiara Cicarelli & Francesca Turco	25/04/2023	25/04/2023	25/04/2023	02/05/2023
1.19	FLASH	Paolo Pertile	28/04/2023	29/04/2023	02/05/2023	03/05/2023
<b>2) INITIATIVES IN OTHER FIELDS THAN HEALTH</b>						
2.1	Water4All	Juliette Arabi	28/02/2023	13/04/2023	14/04/2023	19/04/2023
2.2	FutureFoodS	Gilles Feron	17/04/2023	17/04/2023	17/04/2023	21/04/2023
2.3	SBEP	Maurice Heral	28/02/2023	06/03/2023	07/03/2023	Pending
2.4	FACCE JPI	Heather McKhann	28/02/2023	11/04/2023	11/04/2023	Pending
2.5	Animal Health and Welfare	Agnès Roba	28/02/2023	28/02/2023	07/03/2023	13/03/2023
2.6	NordForsk	Kristin Andersen	28/02/2023	06/03/2023	07/03/2023	14/03/2023
<b>3) INITIATIVES RELATED TO CLINICAL STUDIES AND RESEARCH INFRASTRUCTURES</b>						
3.1	ECRIN	Marta Del Alamo	28/02/2023	02/03/2023	08/03/2023	09/03/2023
3.2	EATRIS	Anton Ussi	08/03/2023	27/03/2023	28/03/2023	31/03/2023
3.3	ESFRI	Dominik Sobczak	03/03/2023	03/03/2023	08/03/2023	10/03/2023

3.4	EUHA	Lynn Seveke	28/02/2023	17/04/2023	17/04/2023	Pending
3.5	Conect4children	Mark Turner	28/02/2023	28/02/2023	08/03/2023	08/03/2023
3.6	MIRRI	Luís Miguel Guimarães Soares	28/02/2023	03/03/2023	07/03/2023	07/03/2023
3.7	ERINHA	Diana Stepanyan	28/02/2023	12/04/2023	07/03/2023	Pending
3.8	EOSC	Ute Gunsenheimer	28/02/2023	28/02/2023	07/03/2023	Pending
3.9	Trials@Home	Mira Zuidgeest	08/03/2023	14/04/2023	14/04/2023	11/05/2023
3.10	COMET	Paula Williamson	08/03/2023	08/03/2023	09/03/2023	09/03/2023
3.11	ELIXIR	Andrew Smith	24/04/2023	02/05/2023	02/05/2023	02/05/2023
3.12	Remedi4All	Christine Kubiak	28/04/2023	28/04/2023	28/04/2023	Pending

The table 2 shows the list of initiatives with potential synergies with E4H but for which no contact person has been found yet or no answer was received for the contact person identified.

An international workshop is being organised to be held in June 2023, in the framework of task 1.3.3 of WP8 to present the initiative and synergies identified. All the partners of E4H, the EC representatives and the members of the SWG will be invited. Regarding those initiatives with no contact person identified or with no feedback received, a selection of the most relevant for E4H will be done and, in order to avoid leaving them without being presented at the workshop, each initiative will be assigned an E4H partner to help with the identification of synergies and to present the initiative at the workshop.



*Table 2: List of initiatives with no member assigned*

Ref	Initiative	Description	Status
<b>1) INITIATIVES IN THE FIELD OF HEALTH</b>			
1.20	GACD	The Global Alliance for Chronic Diseases (GACD) brings together major international research funding agencies specifically to address the growing burden of NCDs in LMICs and vulnerable populations in high-income countries (HICs). The GACD: Invests in impactful NCD implementation research; Builds implementation science capacity and capability in relation to NCDs; Facilitates collaborations and partnerships to support GACD investment and impact. The GACD Research Network of investigators are active in more than 73 countries around the world.	Pending for confirmation
1.21	Horizon Europe - Mission: Cancer	The goal of the Mission on Cancer is to improve the lives of more than 3 million people by 2030, through prevention, cure and for those affected by cancer including their families, to live longer and better. The objectives include: Understand; Prevent what is preventable; Optimise diagnostics and treatment; Support quality of life; Ensure equitable access in all aforementioned areas. The Mission on Cancer will address all cancers including poorly understood cancers in men and women, cancers in children, adolescents and young adults as well as in the elderly, cancers in socio-economically vulnerable populations, living in either cities, rural or remote areas, across all Member States and Associated countries.	Pending for confirmation
1.22	EIT Health-KIC	European Institute of Innovation and Technology Health Knowledge and Innovation Community. By sustaining an ongoing dialogue with all relevant stakeholders, EIT Health synergises its priorities with wider public health priorities (for example the European Commission's Horizon Europe). EIT Health actively supports European Commission bodies in identifying needs, gaps, and opportunities for Europe to develop and scale healthcare solutions.	Pending for confirmation
1.23	B1MG	The Beyond 1 Million Genomes (B1MG) project aims to make it easier to share human health data around Europe. It will support the European Union's 1+ Million Genomes Initiative (1+MG), which aims to provide access to at least one million sequenced genomes in the EU by 2022. The goal is to make the personal genomic data and associated health information accessible in a secure manner for the different purposes in health care (prevention, diagnostics and therapy), research and innovation, and public health.	Pending for confirmation

1.24	Invest4Health	European society is ageing and expectations regarding healthcare services or public health are rising. While improving healthcare system functioning, budgetary pressures will keep increasing. Consequently, in the medium to long-term, governments will have less fiscal space to provide additional budgetary resources, including healthcare. To address this problem, the EU-funded Invest4Health project proposes to design new finance models based on the promotion of health and disease prevention. It will do it through interdisciplinary research and testing for optimal financing solutions in capacitating intelligent investment by creating a model collaborative platform. It would allow shared risks, environmental draws and localised benefits while empowering citizens and communities to invest in new spaces.	Pending for confirmation
1.25	PRUDENT	The PRUDENT (Prioritization, incentives and Resource use for sUustainable DENTistry) project aims to develop and implement an innovative and context-adaptive framework for optimized financing of oral care. PRUDENT brings together top investigators from prestigious universities, public authorities and policymakers, civil society and patient organizations, health insurers, and health professionals, to achieve a step change in collective problem solving. Given the comprehensiveness of the topic, PRUDENT uses a targeted approach that is entirely focused on four major root-causes underlying the current limitations of oral care financing.	Pending for confirmation
<b>2) INITIATIVES IN OTHER FIELDS THAN HEALTH</b>			
2.7	Horizon Europe-Cluster 6	This cluster aims at reducing environmental degradation, halting and reversing the decline of biodiversity on land, inland waters and sea and better managing natural resources through transformative changes of the economy and society in both urban and rural areas. It will ensure food and nutrition security for all within planetary boundaries through knowledge, innovation and digitalisation in agriculture, fisheries, aquaculture and food systems and steer and accelerate the transition to a low carbon, resource efficient circular economy and sustainable bioeconomy, including forestry.	Pending for contact point
2.8	PARC	Partnership for the Assessment of Risks from Chemicals. EU-wide research and innovation partnership programme to support EU and national chemical risk assessment and risk management bodies. PARC will facilitate the transition to next generation risk assessment to better protect human health and the environment, aiming in particular to underpin the concrete implementation of new orientations in European public policies to safeguard health and the environment in response to important issues for health	Pending for contact point
2.9	ERDF	The European Regional Development Fund (ERDF) provides funding to public and private bodies in all EU regions to reduce economic, social and territorial disparities. The Fund supports investments through dedicated national or regional programmes. In 2021-2027, the fund will enable investments to make Europe and its regions: more competitive and smarter, greener, more connected, more social, closer to citizens.	Pending for confirmation

2.10	ESF+	The European Social Fund Plus (ESF+) is the European Union (EU)'s main instrument for investing in people and supporting the implementation of the European Pillar of Social Rights. With a budget of almost EUR 99.3 billion for the period 2021-2027, the ESF+ will continue to provide an important contribution to the EU's employment, social, education and skills policies, including structural reforms in these areas. The Fund will also be one of the cornerstones of EU socio-economic recovery from the coronavirus pandemic. The pandemic has reversed gains in labour participation, challenged educational and health systems and increased inequalities. The ESF+ will be one of the key EU instruments helping Member States to address these challenges. As part of cohesion policy, the ESF+ will also continue its mission to support economic, territorial and social cohesion in the EU – reducing disparities between Member States and regions.	Pending for contact point
<b>3) INITIATIVES RELATED TO CLINICAL STUDIES AND RESEARCH INFRASTRUCTURES</b>			
3.13	BBMRI	BBMRI-ERIC is a European research infrastructure for biobanking that brings together all the main players from the biobanking field – researchers, biobankers, industry, and patients – to boost biomedical research. To that end, they offer quality management services, support with ethical, legal and societal issues, and a number of online tools and software solutions. Ultimately, their goal is to make new treatments possible.	Pending for confirmation
3.14	EU-Openscreen-ERIC	EU-OPENSREEN is a not-for-profit European Research Infrastructure Consortium (ERIC) for chemical biology and early drug discovery. EU-OPENSREEN operates an open-access database and a unique, common compound collection. Our main library, the European Chemical Biology Library (ECBL), consists of over 100.000 compounds. EU-OPENSREEN has over 20 affiliated high-throughput screening and chemistry facilities at partner sites in 10 European countries. These partner facilities provide researchers with access to cutting-edge technologies to develop their own tool compounds.	Pending for contact point
3.15	INFRAFRONTIER	In the INFRAFRONTIER consortium - European Research Infrastructure for Modelling Human Diseases - more than 20 leading biomedical research institutes in 15 countries join forces to investigate the link between gene function and human diseases by the use of model organisms. They contribute to human health by advancing disease prevention and therapies through appropriate models. INFRAFRONTIER is also a part of the European Joint Programme on Rare Diseases (EJP RD).	Pending for contact point
3.16	ECRAID	ECRAID - European Clinical Research Alliance on Infectious Diseases - advances clinical research in the field of infectious diseases by establishing a long-term, financially self-sustainable, clinical research network in Europe. Ecraid offers access to a 'warm base' pan-European clinical research network experienced in delivering rapid, cost-efficient and high-quality clinical research. This unique network can perform a wide range of 'on demand' clinical trials.	Pending for confirmation

3.17	EU-PEARL	EU-PEARL - EU Patient-centric clinical trial platforms - is a strategic partnership between the public and private sectors to shape the future of clinical trials. This innovative and challenging enterprise aims to create a framework for patient-centric integrated research platform (IRP) trials, through which novel techniques and treatments developed by multiple companies and organizations are tested in a platform trial. To achieve this objective, EU-PEARL promotes cooperation amongst pharmaceutical companies, clinicians, patients and researchers and encourages knowledge sharing and open discussion amongst all stakeholders, including regulators.	Pending for confirmation
3.18	EDCTP	EDCTP - European & Developing Countries Clinical Trials Partnership - is a public-public partnership between 15 European and 21 sub-Saharan African countries, supported by the European Union. Its vision is to reduce the individual, social and economic burden of poverty-related infectious diseases in sub-Saharan Africa, by supporting collaborative research to develop accessible, suitable and affordable medical interventions. Its mission is to enhance research capacity and accelerate the development of new or improved medical interventions for the identification, treatment and prevention of poverty-related infectious diseases through all phases of clinical trials.	Pending for confirmation
3.19	EU_AMRI	EU-AMRI - European Alliance of Medical Research Infrastructures - is the collaboration between the European research infrastructures BBMRI-ERIC, EATRIS-ERIC, and ECRIN-ERIC. The three research infrastructures work in parallel to provide complementary services to researchers in the field of biomedical sciences and support the development of personalised medicine and new treatments. IT covers: 3 European Research Infrastructures, over 700 research institutions and university hospitals and 29 European countries as members and observers. It was launched in 2021 but co-operating since 2014.	Pending for confirmation
3.20	EuroBioimaging ERIC	Euro-BioImaging - European Research Infrastructure for Imaging Technologies in Biological and Biomedical Sciences - is a research infrastructure that offers open access to imaging technologies, training and data services in biological and biomedical imaging. Through Euro-BioImaging, life scientists can access imaging instruments, expertise, training opportunities and data management services that they might not find at their home institutions or among their collaboration partners. All scientists, regardless of their affiliation, area of expertise or field of activity can benefit from these pan-European open access services, which are provided with high quality standards by leading imaging facilities.	Pending for contact point
3.21	SHARE ERIC	SHARE, the Survey of Health, Ageing and Retirement in Europe, is a research infrastructure for studying the effects of health, social, economic and environmental policies over the life-course of European citizens and beyond. SHARE has global impact since it not only covers all EU member countries in a strictly harmonized way but additionally is embedded in a network of sister studies all over the world, from the Americas to Eastern Asia.	Pending for confirmation

3.22	CTTI	<p>CTTI - Clinical trials transformation initiative - Mission: To develop and drive adoption of practices that will increase the quality and efficiency of clinical trials.</p> <p>CTTI fosters an open forum for all stakeholders - 500+ organizations and approximately 80 member organizations - to discuss issues, exchange ideas, and come to a consensus on solutions. Through this unique approach of blending diverse viewpoints, our work is actionable; it helps re-shape policies and procedures across the research community to run more efficient trials, generate high-quality evidence faster and, - ultimately - improve the health of people.</p>	Pending for confirmation
3.23	The global health network	<p>The Global Health Network enables easier, faster, and better research in the world's most challenging settings.</p> <p>The Global Health Network works across all aspects of health research to address the following aims: 1) To embed health research in places, diseases and regions where evidence is lacking by bringing support, training and guiding faster, easier and better research processes. 2) To drive equity in who takes part and who benefits from health research by enabling the open movement of health research information, data and know-how between diseases areas, regions, organisations and communities. 3) To build lasting capable research teams in low-resource settings who are able to lead research studies and compete internationally for recognition, reward, engagement and visibility.</p>	Pending for confirmation
3.24	EMA	<p>The European Medicines Agency (EMA) is a decentralised agency of the European Union (EU) responsible for the scientific evaluation, supervision and safety monitoring of medicines in the EU. The mission of the European Medicines Agency (EMA) is to foster scientific excellence in the evaluation and supervision of medicines, for the benefit of public and animal health in the European Union (EU).</p>	Pending for contact point

The next section of the deliverable shows the description of each initiative and the profile of the member of the SWG for each initiative.

## 1) INITIATIVES IN THE FIELD OF HEALTH

**Reference: 1.1**

**European Initiative: JPI HDHL**

Coordinating research in the area of nutrition, diet, health and physical activity: The Joint Programming Initiative a Healthy Diet for a Healthy Life (JPI HDHL) brings together 20 countries that align research programming and fund new research to prevent or minimise diet-related chronic diseases.

Member of the SWG:



Name and Surname:

**Jessie Doppler**

Organisation:

ZonMw

Brief CV (the entire profile is expected to take up one page):

As the Coordinator of JPI HDHL (Joint Programming Initiative A Healthy Diet for A Health Life) and Senior Program Manager at The Netherlands Health Research and Development Organisation (ZonMw), I specialise in science and policy in the fields of nutrition, health, lifestyle and sustainable food systems. I create connections, implement and foster cooperation in multi-stakeholder collaborative projects, while focusing on external engagement, communications and aligning research and its impact across the European landscape. I am committed to high-level strategic planning in the context of transnational collaborations and translating them from science to policy.

I am a curious and multilingual professional with a background in intercultural communications, international cooperation and business development having gained experience working in France, Austria, the UK, Germany and The Netherlands.

Over the years, I have worked with a wide range of stakeholders spanning across government, NGOs, academia and industry.

**Reference: 1.2**

**European Initiative: Horizon Europe – Cluster 1**

The aims of this cluster include improving and protecting the health and well-being of citizens of all ages by generating new knowledge, developing innovative solutions and integrating where relevant a gender perspective to prevent, diagnose, monitor, treat and cure diseases. Further aims include developing health technologies, mitigating health risks, protecting populations and promoting good health and well-being in general and at work. Finally, this cluster also aims to make public health systems more cost-effective, equitable and sustainable, prevent and tackle poverty-related diseases and support and enable patients' participation and self-management.

Member of the SWG:

Not a formal member of the SWG, but EC representative will be invited to attend the SWG meetings as observer.

Name and Surname:

EC Representative

### Reference: 1.3

#### European Initiative: EUHealth Programme


EU4Health is the EU's largest health programme in monetary terms, with a budget of €5.3 billion in current prices. The EU4Health programme goes beyond an ambitious response to the COVID-19 crisis to address the resilience of European healthcare systems. EU4Health provides funding to national authorities, health organisations and other bodies through grants and public procurement, contributing to a healthier Europe. The EU4Health programme is a key pillar to the Commission's work to strengthen the European Health Union and contribute to the EU's health priorities. The actions funded under the EU4Health programme pursue 4 goals and 10 specific objectives. EU4Health will also be investing in urgent health priorities: response to COVID-19 pandemic and resilience for cross-border health threats; Europe's Beating Cancer Plan; The Pharmaceutical Strategy for Europe. And other areas: the digitalisation of health systems, antimicrobial resistance, improved vaccination rates.

Member of the SWG:

**Receipt of documents is pending (Profile form / Statement of Acceptance)**

Name and Surname:

**Adrian Peres**

<b>Reference: 1.3</b>
<b>European Initiative: EUHealth Programme</b>
<p>EU4Health is the EU’s largest health programme in monetary terms, with a budget of €5.3 billion in current prices. The EU4Health programme goes beyond an ambitious response to the COVID-19 crisis to address the resilience of European healthcare systems. EU4Health provides funding to national authorities, health organisations and other bodies through grants and public procurement, contributing to a healthier Europe. The EU4Health programme is a key pillar to the Commission’s work to strengthen the European Health Union and contribute to the EU's health priorities. The actions funded under the EU4Health programme pursue 4 goals and 10 specific objectives. EU4Health will also be investing in urgent health priorities: response to COVID-19 pandemic and resilience for cross-border health threats; Europe’s Beating Cancer Plan; The Pharmaceutical Strategy for Europe. And other areas: the digitalisation of health systems, antimicrobial resistance, improved vaccination rates.</p>
<b>Member of the SWG:</b>

<b>Name and Surname</b>
<b>María José González de Suso</b>
<b>Organisation</b>
Instituto de Salud Carlos III (ISCIII)
<b>Brief CV (the entire profile is expected to take up one page)</b>
<p>PhD in Medicine and Surgery. Specialist in Clinical Pharmacology (MIR) and Diploma in Medicine in the Pharmaceutical Industry (UCM). Senior Management Programme in Health Institutions (IESE), Advanced Course in Patents and Technology Transfer (Pons-URJC Foundation) and Master's Degree in R&amp;D&amp;I Management in Health Sciences (ISCIII-UAH-UNED).</p> <p>She has developed his professional career in several areas: in the health care field (NHS Clinical Hospitals in Granada and Madrid), in the National Government (ISCIII and MoHealth), and in Scientific Departments in the private sector of the Pharmaceutical Industry (Bristol-Myers Squibb).</p> <p>From 2007 to the present, she has been working as Director of Programmes in the International Research Programmes and Institutional Relations Department of the Institute of Health Carlos III (ISCIII) - Ministry of Science and Innovation.</p> <p>Since 2014, she acts as the National Focal Point Representative for Spain for the EU Health Programme of DG SANTÉ of the European Commission, having been appointed to hold this position by the MoHealth.</p> <p>Among other European Research Funding Programmes, she also interacts with AAL -Ambient Assisted Living- and JPI MYBL- Joint Programming Initiative More Years Better Life of Horizon Europe, as well as</p>



with IARC- International Agency for Research on Cancer- of the WHO, and other international organisations and institutions in the field of biomedicine.

**Reference: 1.4**

**European Initiative: TRANSCAN-3**

Transnational cancer research is key for addressing, understanding and preventing cancer, a worldwide health concern despite the continuous advancement of research and treatment approaches. The EU-funded TRANSCAN-3 project is bringing together 31 funding organisations from 20 countries, with the common goal of supporting high-impact translational cancer research. Through cross-national joint calls for proposals and making the most of international and interregional cooperation, TRANSCAN-3 aims to provide influential contributions as well as a sustainable model of funding for ground-breaking translational cancer research in Europe and beyond.

**Member of the SWG:**



**Name and Surname**

**Inés Rey Hidalgo**

**Organisation**

FICYT

**Brief CV (the entire profile is expected to take up one page)**

I will contribute to the SWG as partner of the ERANET TRANSCAN-3, which is a s bringing together 31 funding organisations from 20 countries, with the common goal of supporting high-impact translational cancer research.

I am the manager of the Office of European Projects of FICYT. I have carried out the administrative and financial coordination of three European projects in the field of health and participated as partner in other 11 European projects.

Regarding ERANETs and Partnerships, I take part in the FICYT's team as partner of TRANSCAN-2, TRANSCAN-3, ERA4Health, CETP and FutureFoodS.

I have been working in FICYT managing the regional funding calls launched in the framework of the ERANETs and Partnerships international calls.

**Reference: 1.5**
**European Initiative: ERA PerMed**

ERA PerMed is an ERA-Net Cofund, supported by 32 partners from 23 countries and cofunded by the European Commission. The main objective of ERA PerMed is to align national research strategies, promote excellence, reinforce the competitiveness of European players in Personalised Medicine, and enhance the European collaboration with non-EU countries. National funding organisations will launch Joint Transnational Calls for collaborative research projects in Personalised Medicine.

Member of the SWG:



Name and Surname

**María Cristina Nieto García**

Organisation

Instituto de Salud Carlos III (ISCIII)

Brief CV (the entire profile is expected to take up one page)

Dr. María Cristina Nieto García is currently Head of the International Research Programmes Unit in the Deputy Director's Office for International Research Programmes and Institutional Relations (SGPIIRI) in the National Institute of Health Carlos III (ISCIII). She is actively involved in the coordination, management and follow-up of different programmes related to European and International transnational collaborative research at SGPIIRI. She is the coordinator of ERA4Health Partnership and the coordinator of ERA-Net Co-fund ERA-PerMed. She is also the Spanish representative of the CSA ICPeMed Secretariat and member of the preparatory group of the future Partnership of Personalised Medicine (EP PerMed).

Previously, she obtained her PhD in Pharmacy in the Cancer Research Centre of the University of Salamanca in 2011, followed by a multi-year stint as Pharmaceutical Inspector for the Spanish Government. Afterwards, she worked for the Spanish Ministry of Science in Knowledge Transfer and Science Management activities.

**Reference: 1.6**

**European Initiative: EJP RD**

The European Joint Programme on Rare Diseases (EJP RD) is a programme aiming to create an effective rare diseases research ecosystem for progress, innovation and for the benefit of everyone with a rare disease. They support rare diseases stakeholders by funding research, bringing together data resources & tools, providing dedicated training courses, and translating high quality research into effective treatments. EJP RD brings over 130 institutions (including all 24 ERNs) from 35 countries: 26 EU Member States (Austria, Belgium, Bulgaria, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Croatia, Ireland, Italy, Netherlands, Latvia, Lithuania, Luxembourg, Malta, Poland, Portugal, Romania, Spain, Sweden, Slovakia, Slovenia); 7 associated (Armenia, Georgia, Israel, Norway, Serbia, Switzerland, Türkiye); Uk & Canada.

Member of the SWG:



Name and Surname

**Daria Julkowska**


Organisation

INSERM

Brief CV (the entire profile is expected to take up one page)

Daria Julkowska has a PhD in molecular biology and pursued her scientific vocation by the post-doctoral experience in cellular biology, at Institut Pasteur, Paris and extensive training in communication and European Union counselling. She also holds MSc in Management of Research from the University of Paris Dauphine. She is the Scientific Coordinator of the European Joint Programme on Rare Diseases that brings together over 130 institutions representing different type of stakeholders (researchers, funders, clinicians & patients) from 35 countries from Europe and beyond, and is also responsible for the coordination of the IRDiRC Scientific Secretariat. She is involved in the rare diseases field since 2010. She developed and put into action a set of collaborations facilitating research, including the partnerships with European Research Infrastructures and Patients' Organizations. She has an extensive knowledge and understanding of European funding schemes and programmes and serves as the chair of the Expert Group on support for the strategic coordinating process for European partnerships of the European Commission. In 2020 she received EURORDIS Black Pearls Award for the European Rare Diseases Leadership.

**Reference: 1.7**

<b>European Initiative: JPIAMR</b>
The Joint Programming Initiative on Antimicrobial Resistance, JPIAMR, is an international collaborative organization and platform, engaging 29 nations and the European Commission to curb antimicrobial resistance (AMR) with a One Health approach. The JPIAMR coordinates national research funding and supports collaborative action for filling knowledge gaps on AMR with a One Health perspective. Their shared Strategic Research and Innovation Agenda outlines the key areas to be addressed and provides guidance for countries to align their AMR research agendas nationally and internationally.
Member of the SWG:

Name and Surname
<b>Laura Marin</b>
Organisation
Swedish Research Council
Brief CV (the entire profile is expected to take up one page)
Laura Marin coordinates the Joint Programming Initiative on Antimicrobial Resistance (JPIAMR) initiative and heads its Executive office Secretariat hosted by the Swedish Research Council. JPIAMR, is an international collaborative platform that coordinates national research funding and supports collaborative research action for filling knowledge gaps on antimicrobial resistance with a One Health perspective. She also leads the preparations of the future European co-funded One Health AMR Partnership. Previously she was responsible for Science Policy and Member Relations at the European Science Foundation in Strasbourg. Earlier on she was team leader of the European Science Open Forum in 2008 and Director of Operations at the Catalan Foundation for Research and Innovation. She has several years of experience in Brussels and Germany managing research and innovation projects and facilitating numerous fora on science policy. She holds a M.Litt in Management, Economics and International Relations from University of St. Andrews, a M.S.c & B.A. in Political Science and Public Administration from Universitat Autònoma de Barcelona and has followed business executive education at IMD Business School Lausanne.

<b>Reference: 1.8</b>
<b>European Initiative: IHI</b>
The Innovative Health Initiative (IHI) is a public-private partnership (PPP) in health between the European Union and the European life science industries, that runs under Horizon Europe, the European

framework programme for research and innovation. Their core goals are to translate health research and innovation into tangible benefits for patients and society, and ensure that Europe remains at the cutting edge of interdisciplinary, sustainable, patient-centric health research.

Member of the SWG:



Name and Surname

**Magali Poinot**

Organisation

IHI JU

Brief CV (the entire profile is expected to take up one page)

Team Leader the Governance Cell of the IHI JU, Magali Poinot oversees the activities relating to the IHI JU Governing Board, Science and Innovation Panel and States' Representatives Group. An important role of coordinating the Task Force on Synergies with other programmes and initiatives, and the preparation of the annual work programmes are also key parts of the function.

During the setting-up of and transition towards IHI JU, Magali acted as the IMI JU focal point for shaping with the European Commission services and the industry partners the new cross-sectorial public-private partnership in Health under Horizon Europe.

Lawyer by training, Magali Poinot is specialised in European Community-funded Research & Development and Innovation programmes (including coordination of national research programs and setting up of major European initiatives) and in Intellectual Property management in transnational collaborative research projects.


Before joining the European Commission (Directorate General Research & Innovation) during several years, Magali worked for French high engineers' schools Ecoles des Mines, a range of intergovernmental initiatives in the field of Science and Technology (such as COST and EUREKA) and coordinated the European IPR-Helpdesk (assistance and support on Intellectual Property to applicants and participants of EU-funded projects). She is also a Board member of the Global Healthcare Innovation Alliance Accelerator (GHIAA).

**Reference: 1.9**

**European Initiative: EP PerMed**

ICPerMed promotes the establishment of a European Partnership for Personalised Medicine, EP PerMed, together with the closely connected ERA-Net ERA PerMed.

Deadlines: SRIA finalization (02/2023) / EP PerMed proposal (04/2023) / EP PerMed lifetime (Q4/2023-2030).

<b>Member of the SWG:</b>

<b>Name and Surname</b>
<b>Wolfgang Ballensiefen</b>
<b>Organisation</b>
DLR PT
<b>Brief CV (the entire profile is expected to take up one page)</b>
<p><u>Profile</u></p> <ul style="list-style-type: none"> <li>•Project management for health research funding measures on the European level and nationally on behalf of the German Federal Ministry of Education and Research</li> <li>•Policy advise, e.g. in the areas of personalised medicine and cardiovascular research</li> <li>•Author or co-author of several strategic European publications in the area of health research, e.g. the Vision Paper of the International Consortium for Personalised Medicine, the Strategic Research Agenda for Cardiovascular Diseases (SRA-CVD) or the Strategic Research and Innovation Agenda for personalised Medicine (SRIA PerMed),</li> <li>•Expertise in a wide range of public relation activities, e.g. press workshops and disease-specific publications</li> <li>•Publications (peer review)</li> </ul> <p><u>References</u></p> <p>Since 2022; Coordinator of the EP PerMed proposal and the related SRIA 2023. Since 2021; Coordinator of the Coordination and Support Action (CSA) ICPeMed Secretariat. 2019-2022; Coordinating partner of the CSA for Strengthening Training of Academia in Regulatory Science (CSA STARS). 2019-2022; Partner of the CSA to develop Health Economic and Payment Models for Personalised Medicine (CSA HECoPerMed). From 2016; Representative of the German Federal Ministry for Education and Research and until 2020 vice-chair of the International Consortium for Personalised Medicine (ICPerMed). 2015-2022; Coordinator of the ERA-Net Cofund action dedicated to cardiovascular diseases and co-funded by the European Commission, ERA-CVD. 2013 – 2015 Coordinator of the CSA for Personalised Medicine (CSA PerMed)</p> <p><u>Work Experience</u></p> <ul style="list-style-type: none"> <li>- Since 2000: German Aerospace Center, Project Management Agency, Health (ID-GE), Innovation for disease related research, Personalised Medicine (GE-IKB)</li> <li>- 1997 – 2000: Researcher (Postdoc) at the Medical Research Council (MRC) Laboratory for Molecular Cell Biology (LMBC) at the University College in London (UCL)</li> </ul>

<b>Reference: 1.10</b>
<b>European Initiative: BE READY</b>

The main goal of BE READY is to build a consolidated European Research and Innovation Area that provides the foundation of the candidate European partnership for pandemic preparedness so to improve the EU's preparedness to predict and respond to emerging health threats by better coordinating funding for research and innovation at EU, national (and regional) level towards common objectives and an agreed Strategic Research and Innovation Agenda. The Partnership is expected to build on existing pandemic preparedness networks, and work in synergy with the Health Emergency Response Authority (HERA), in close collaboration with ECDC, EMA and other relevant international and European actors. BE READY is composed by 24 organisations from 15 countries with complementary expertise and policy area ranging from Public Health Organisations, Ministries (of Science, University, Health, Innovation or Environment) and Research Performing Organisations that ensures a cross-cutting, interdisciplinary Global Health and One Health approach.

Member of the SWG:



Name and Surname

**Hervé Raoul**

Organisation

ANRS Emerging Infectious Diseases

Brief CV (the entire profile is expected to take up one page)

Education

PhD in Biology of Blood Cells (1995, University of Paris 7, France)

Accreditation to supervise research (HDR) in Toxicology (2000, University of Paris XI, France).

Work History

Hervé Raoul is Director of Research at Inserm and Deputy Director of the ANRS-MIE (ANRS – Emerging Infectious Diseases) since July 2021. He has been Director of the Inserm Jean Mérieux BSL4 laboratory located in Lyon from October 2005 to September 2022. He is and has been actively involved in various international collaborations and in European-funded programs and has created in July 2017 the pan-European infrastructure dedicated to RG4 pathogens study. He is member of various national and international scientific advisory boards.

**Reference: 1.11**

**European Initiative: ERA Net NEURON**



This initiative was launched under the 6th Framework Programme of the European Commission as an ERA-NET – a platform to coordinate collaborative action between funding bodies and foster a European Research Area (ERA). The participating partner organisations are major stakeholders and provide considerable funding for disease-related neuroscience in their countries. They agree that excellent research is a prerequisite to overcome the societal burden of brain diseases and that such research requires promotion and investment in an internationally concerted action. NEURON partners support research that is directed at a better understanding of brain and nervous system diseases and their progression in order to pave the way for new or improved routes for diagnosis and therapy.

Member of the SWG:



Name and Surname

**Dr. Hella Lichtenberg**

Organisation

DLR e.V. Project Management Agency | Health Research

Brief CV (the entire profile is expected to take up one page)


Hella Lichtenberg, PhD, ERA-NET NEURON is a trained geneticist with a habilitation in microbiology. Since 2007 she is responsible for NEURON's, since 2015 was also for ERA-CVD's (Cardiovascular Diseases) coordination office, and was since 2018 actively engaged in the EBRA project (Brain Research). The involvement in the international measures necessitates all areas of conceptualizing and executing research funding programmes including overarching topics like PPI, quality assurance in biomedical research, and ethical issues.

**Reference: 1.12**

**European Initiative: JPND Research**

JPND aims to confront the growing challenge posed by neurodegenerative diseases in our ageing population by bringing together researchers, existing research evidence and national funding bodies to investigate the key research questions and barriers to progress in this area. The neurodegenerative diseases that JPND focuses on are: Alzheimer's disease (AD) and other dementias; Parkinson's disease (PD) and PD-related disorders; Prion disease; Motor neurone diseases (MND); Huntington's disease (HD); Spinocerebellar ataxia (SCA); Spinal muscular atrophy (SMA).



Member of the SWG:

Name and Surname:
<b>Philippe Amouyel</b>
Organisation
Lille university / Inserm / Institut Pasteur de Lille
Brief CV (the entire profile is expected to take up one page)
<p>Professor of Epidemiology and Public Health at the medical School and University Hospital of Lille, France (PU-PH)</p> <p>Philippe Amouyel, MD, PhD, chairs the EU Joint Programme on Neurodegenerative Diseases research (JPND), a 30-country led initiative aimed at tackling the challenge of neurodegenerative diseases, the largest global research collaboration on neurodegenerative diseases. He is Professor of Epidemiology and Public Health at the University Hospital of Lille in France. He heads a large academic research unit working on public health and molecular epidemiology of aging diseases. He develops epidemiological studies to attempt to decode susceptibility to ageing diseases, using molecular techniques such as high-throughput genomics, transcriptomics, proteomics, and bioinformatics. His research is devoted to the study of determinants, mainly genetic, of neurodegenerative diseases associated with cognitive decline and Alzheimer's disease in particular. He participated in the discovery of more than 90% of the genetic susceptibility published in Alzheimer's disease. He published 749 original articles and reviews in international journals (h-index = 122; average citations per item 115; highly cited researcher 2018, Web of Science, Clarivate). Since 2008, he has been the general director of Fondation Alzheimer (France), a private non-profit foundation dedicated to supporting innovative and cutting-edge research for Alzheimer's disease and related disorders.</p> <p>Main publications</p> <p><i>Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease.</i> Lambert JC et al., Nat Genet 2013;45:1452-1458</p> <p><i>Defeating Alzheimer's disease and other dementias: a priority for European science and society.</i> Winblad B, Amouyel P, Andrieu S et al., Lancet Neurol. 2016;15:455-532</p> <p><i>Global Alzheimer's disease and Alzheimer's disease related dementia research funding organizations support and engage the research community throughout the COVID-19 pandemic.</i> Meyers EA, Amouyel P et al., Alzheimers Dement 2022;18:1067-1070</p> <p><i>New insights into the genetic etiology of Alzheimer's disease and related dementias.</i></p>

Bellenguez C et al., Nat Genet. 2022;54:412-436

**Reference: 1.13**

**European Initiative: OH AMR Partnership**

The CSA DESIGN OH AMR, in collaboration with JPIAMR and other stakeholders is leading the development of the One Health AMR Partnership. The main goal is to contribute to achieving the objectives of the European One Health Action Plan against AMR and the WHO Global Action Plan on AMR, both aimed at reducing the threat of antimicrobial resistance (AMR). The SRIA and proposal submission to the EC is foreseen in 2024. The first call and launch of other activities of this joint research programme between the European Commission and Member States are planned to take place in 2025.

Member of the SWG:



Name and Surname


**Laura Marin**

Organisation

Swedish Research Council

Brief CV (the entire profile is expected to take up one page)

Laura Marin coordinates the Joint Programming Initiative on Antimicrobial Resistance (JPIAMR) initiative and heads its Executive office Secretariat hosted by the Swedish Research Council. JPIAMR, is an international collaborative platform that coordinates national research funding and supports collaborative research action for filling knowledge gaps on antimicrobial resistance with a One Health perspective. She also leads the preparations of the future European co-funded One Health AMR Partnership. Previously she was responsible for Science Policy and Member Relations at the European Science Foundation in Strasbourg. Earlier on she was team leader of the European Science Open Forum in 2008 and Director of Operations at the Catalan Foundation for Research and Innovation. She has several years of experience in Brussels and Germany managing research and innovation projects and facilitating numerous fora on science policy. She holds a M.Litt in Management, Economics and International Relations from University of St. Andrews, a M.S.c & B.A. in Political Science and Public Administration from Universitat Autònoma de Barcelona and has followed business executive education at IMD Business School Lausanne.

<b>Reference: 1.14</b>
<b>European Initiative: ICP PerMed</b>
ICPerMed provides a platform to initiate and support communication and exchange on personalised medicine research, funding and implementation, in which over 30 European and international partners representing ministries, funding agencies and the European Commission (EC) work together on coordinating and fostering research to develop and evaluate personalised medicine approaches.
Member of the SWG:

Name and Surname
<b>Wolfgang Ballensiefen</b>
Organisation
DLR PT
Brief CV (the entire profile is expected to take up one page)
<p><u>Profile</u></p> <ul style="list-style-type: none"> <li>•Project management for health research funding measures on the European level and nationally on behalf of the German Federal Ministry of Education and Research</li> <li>•Policy advise, e.g. in the areas of personalised medicine and cardiovascular research</li> <li>•Author or co-author of several strategic European publications in the area of health research, e.g. the Vision Paper of the International Consortium for Personalised Medicine, the Strategic Research Agenda for Cardiovascular Diseases (SRA-CVD) or the Strategic Research and Innovation Agenda for personalised Medicine (SRIA PerMed),</li> <li>•Expertise in a wide range of public relation activities, e.g. press workshops and disease-specific publications</li> <li>•Publications (peer review)</li> </ul> <p><u>References</u></p> <p>Since 2022; Coordinator of the EP PerMed proposal and the related SRIA 2023. Since 2021; Coordinator of the Coordination and Support Action (CSA) ICPPerMed Secretariat. 2019-2022; Coordinating partner of the CSA for Strengthening Training of Academia in Regulatory Science (CSA STARS). 2019-2022; Partner of the CSA to develop Health Economic and Payment Models for Personalised Medicine (CSA HEcoPerMed). From 2016; Representative of the German Federal Ministry for Education and Research and until 2020 vice-chair of the International Consortium for Personalised Medicine (ICPerMed). 2015-2022; Coordinator of the ERA-Net Cofund action dedicated to cardiovascular diseases and co-funded by the European Commission, ERA-CVD. 2013 – 2015 Coordinator of the CSA for Personalised Medicine (CSA PerMed)</p> <p><u>Work Experience</u></p> <p>- Since 2000: German Aerospace Center, Project Management Agency, Health (ID-GE), Innovation for disease related research, Personalised Medicine (GE-IKB)</p>

- 1997 – 2000: Researcher (Postdoc) at the Medical Research Council (MRC) Laboratory for Molecular Cell Biology (LMBC) at the University College in London (UCL)

**Reference: 1.15**

**European Initiative: IRDiRC**

IRDiRC is a global collaborative initiative launched in 2011 by the European Commission and the US National Institutes of Health to tackle rare diseases through research and accomplish the vision to enable all people living with a rare disease to receive an accurate diagnosis, care, and available therapy within one year of coming to medical attention.

Today, the Consortium gathers 60 member organizations from all continents. Members’ representatives are organized into the Constituent Committees of Funders, Companies and Umbrella Patient Advocacy Groups, and collaborate with international experts nominated into the Diagnostics, Therapies and Interdisciplinary Scientific Committees.

Through its broad representation, IRDiRC works towards the mission of advancing diagnostics and treatments, and of understanding the impact of these, for all people living with a rare disease (specific Task Force on Clinical Research Networks for Rare Diseases).

Member of the SWG:



Name and Surname


**Daria Julkowska**


Organisation

INSERM

Brief CV (the entire profile is expected to take up one page)

Daria Julkowska has a PhD in molecular biology and pursued her scientific vocation by the post-doctoral experience in cellular biology, at Institut Pasteur, Paris and extensive training in communication and European Union counselling. She also holds MSc in Management of Research from the University of Paris Dauphine. She is the Scientific Coordinator of the European Joint Programme on Rare Diseases that brings together over 130 institutions representing different type of stakeholders (researchers, funders, clinicians & patients) from 35 countries from Europe and beyond, and is also responsible for the coordination of the IRDiRC Scientific Secretariat. She is involved in the rare diseases field since 2010. She developed and put into action a set of collaborations facilitating research, including the partnerships with European Research Infrastructures and Patients’ Organizations. She has an extensive knowledge and understanding of European funding schemes and programmes and serves as the chair of the Expert Group on support for the strategic coordinating process for European partnerships of the European Commission. In 2020 she received EURORDIS Black Pearls Award for the European Rare Diseases Leadership.


<b>Reference: 1.16</b>
<b>European Initiative: EU-Africa PerMed Project</b>
The EU-Africa PerMed project has the overall aim of integrating African countries into ICPeMed activities, thus contributing to a successful implementation of Personalised Medicine (PM) in the global context. It will foster joint PM projects and programmes between Europe and Africa, as well as strengthening bilateral EU-AU science, technology and innovation (STI) relations in the area of health. The project started on the 1st. of February 2021 and will last 4 years. It is implemented by a consortium of 13 partners, 6 from Europe and 7 from Africa and is organized around 7 main Work Packages.
Member of the SWG:

Name and Surname
<b>Erika Sela</b>
Organisation
INNOVATEC
Brief CV (the entire profile is expected to take up one page)
Erika Sela is Senior Consultant and co-founder of Innovatec, a Spanish consultancy firm with a broad and long-term expertise in R&I activities. She has a bachelor's degree in Biology. She has over 30 years' experience in R&D management activities in different positions and organizations. In the last years, her main activity has been dedicated to European projects. She is now the coordinator of the H2020 project <b>EU-Africa PerMed: Building Links Between Europe and Africa in Personalised Medicine</b> . The project seeks to facilitate and strengthen research and innovation collaboration between Europe and Africa in Personalised Medicine (PM), fostering joint projects and programmes as well as facilitating the participation of African organizations in the international Consortium for Personalized Medicine (ICPerMed).

<b>Reference: 1.17</b>
<b>European Initiative: CSA IC2PerMed</b>
Integrating China in the International Consortium for Personalised Medicine (IC2PerMed) project aims to support EU-China collaboration over the developments of Personalised Medicine research, innovations and policies through the ICPeMed initiative, providing people with access to personalised, smart and inclusive healthcare solutions in the near future.
Member of the SWG:

Name and Surname
<b>Stefania Boccia</b>
Organisation
Section of Hygiene, Institute of Public Health, Università Cattolica del Sacro Cuore (UCSC), Fondazione Policlinico Universitario A. Gemelli (FPG) IRCCS, Rome, Italy
Brief CV (the entire profile is expected to take up one page)
<p>Stefania Boccia is Full professor of Hygiene, Preventive Medicine and Public Health at UCSC in Rome, and Research Director for IRCCS FPG.</p> <p>She is Deputy Research Director of the IRCCS FPG and Affiliate of the Meta-Research Innovation Center at Stanford, Stanford, UK.</p> <p>She is the President of the European Public Health Epidemiology Section of the European Public Health Association (EUPHA), Associate Editor of European Journal of Epidemiology and European Journal of Public Health, Member of the Advisory Board of the Lancet Regional Health-Europe.</p> <p>She currently coordinates the EU funded projects “European network staff eXchange for integrAting precision health in the health Care sysTems” (ExACT) and “A PeRsOnalized Prevention roadmap for the future HEalThcare” (PROPHET).</p> <p>She coordinates the “Interaction of genomic and dietary aspects in gastric cancer risk: the global StoP project” project, funded by the Italian Ministry of Health, Bando 2022 Ricerca Finalizzata, the “Innovative approaches for personalised cardiovascular prevention: multicentre randomised controlled study and multidisciplinary evaluation for a National Health Service implementation” project, funded by the Italian Ministry of Health, PNRR: M6/C2_CALL 2022, and the “Generation Gemelli: longitudinal study for the evaluation of maternal exposome on the newborn and child health” project, funded by UCSC (linea D3, University research projects of interest).</p> <p>She has an H index of 52 and 9702 citations at march 2023</p>

<b>Reference: 1.18</b>
<b>European Initiative: THCS Partnership</b>
<p>The general objective of the European Partnership “Transforming Health and Care Systems” is to contribute to the transition towards more sustainable, efficient, resilient, inclusive, innovative and high-quality people-centred health and care systems equally accessible to all people. For this purpose, THCS aims not only to create new knowledge and scientific evidence but to co-design new solutions and support their transfer and scale-up across countries and regions while also fostering capacity building. The approach for a successful and smooth implementation of THCS will focus on three main work streams: 1) Filling the knowledge gaps with research actions aiming at providing the necessary evidence, 2) Implementation and transfer aiming at supporting actions focusing on the testing of existing solutions and adaptability in different national and regional contexts, and 3) Boosting health and care systems through dedicated activities (capacity building and trainings, study visits, technical assistance, twinning, networking) involving different health and care stakeholders.</p>

<b>Name and Surname</b>
<b>Chiara Ciccarelli</b>
<b>Organisation</b>
Italian Ministry of Health
<b>Brief CV (the entire profile is expected to take up one page)</b>
<p>Chiara Ciccarelli is an International Relations Officer at the Italian Ministry of Health, Directorate General for Research and Innovation in Healthcare.</p> <p>She has an MD in Translation for special purposes focused on legal and medical sectors and is currently achieving a Master’s in Management and Government of Public Administrations as well as a second MD in Political Sciences and International Relations.</p> <p>She is in charge of supervising the International Biomedical Research activities the Italian Ministry of Health is involved in through its IRCCS (Scientific Institute for Research, Hospitalization and Healthcare). She has been involved in several initiatives clustered in the FP “Horizon 2020” and is currently involved in further actions supported by the FP “Horizon Europe”, among which, is the European Partnership “Transforming Health and Care Systems”, of which the Italian Ministry of Health is the coordinator.</p> <p>Moreover, she also supports the Italian Ministry of Foreign Affairs and International Cooperation in the scientific activities jointly carried out under the Scientific and Technological Bilateral Cooperation Agreements.</p>



<b>Reference: 1.18</b>
<b>European Initiative: THCS Partnership</b>
<p>The general objective of the European Partnership “Transforming Health and Care Systems” is to contribute to the transition towards more sustainable, efficient, resilient, inclusive, innovative and high-quality people-centred health and care systems equally accessible to all people. For this purpose, THCS aims not only to create new knowledge and scientific evidence but to co-design new solutions and support their transfer and scale-up across countries and regions while also fostering capacity building. The approach for a successful and smooth implementation of THCS will focus on three main work streams: 1) Filling the knowledge gaps with research actions aiming at providing the necessary evidence, 2) Implementation and transfer aiming at supporting actions focusing on the testing of existing solutions and adaptability in different national and regional contexts, and 3) Boosting health and care systems through dedicated activities (capacity building and trainings, study visits, technical assistance, twinning, networking) involving different health and care stakeholders.</p>

<b>Name and Surname</b>
<b>Francesca Turco</b>
<b>Organisation</b>
Italian Ministry of Health
<b>Brief CV (the entire profile is expected to take up one page)</b>
<p>Francesca Turco is a Health Officer at the Italian Ministry of Health, Directorate General for Research and Innovation in Healthcare.</p> <p>She is a biologist, specialising in Nutrition Science. She worked at various facilities in the National Health System, such as the hospital oncology and preventive dietetics clinics departments.</p> <p>She is involved in both National Finalized and Current Research. In the area of Finalized Research, she is in charge of monitoring and scientifically evaluating the interim and final reports concerning the funded projects submitted by the IRCCS, controlling also the validity and consistency of the related documents. In the area of Current Research, she is in charge of evaluating the compliance of the produced publications with the evaluation criteria established within the IRCCS triennial planning.</p> <p>She has been involved in several initiatives clustered in the FP “Horizon 2020” and is currently involved in further actions supported by the FP “Horizon Europe”, among which, is the European Partnership “Transforming Health and Care Systems”, of which the Italian Ministry of Health is the coordinator.</p>



<b>Reference: 1.19</b>
<b>European Initiative: FLASH - Flexible Approaches to Support Health through Financing</b>
FLASH, a Horizon Europe project (Topic: “Better Financing Models for Health Systems”; 2023-2026), undertakes a comprehensive analysis of health care financing mechanisms in Europe and, by employing a wide range of methodological approaches, it provides evidence on the ability of existing financing mechanisms and contracts to address such challenges and study new solutions to achieve more effective, efficient and equitable health care systems.

Name and Surname
<b>Paolo Pertile</b>
Organisation
University of Verona (Italy)
Brief CV (the entire profile is expected to take up one page)
<p>Current Position :</p> <p>Professor of Public Economics, Department of Economics, University of Verona.          Leader of the research unit of the University of Verona, coordinator of the project FLASH (Flexible Approaches to support Health through Financing).</p> <p>Education:</p> <ul style="list-style-type: none"> <li>• Ph.D; “Graduate School in the Economics and Finance of Public Administration”, a joint programme of Catholic University, Bicocca University and University of Milan (Milan, Italy)</li> <li>• MSc. in “Public Economics”, University of York (UK)</li> <li>• B.A. (4-year degree) in “Economics and Business”. University of Verona (Italy).</li> </ul> <p>Research interests:</p> <p>Economic implications of health care regulation (payment rules, competition), pharmaceutical regulation and innovation, economic evaluation of health care interventions (methodology and applications), economic implications of public sector intervention over the life-cycle.</p> <p>Selected publications:</p> <ul style="list-style-type: none"> <li>• “R&amp;D and market size: who benefits from orphan drug legislation?”; Journal of Health Economics; 2021; vol 80 (with S. Gamba and L. Magazzini).</li> <li>• “The impact of Managed Entry Agreements on pharmaceutical prices”; Health Economics; 2020; vol 29 S1, pp. 47-62 (with S. Gamba e S. Vogler).</li> <li>• “Which valued-based price when patients are heterogeneous?”; Health Economics; 2020; vol 29, pp. 923-935. (with R. Levaggi).</li> <li>• “A Bayesian Decision-Theoretic Model of Sequential Experimentation with Delayed Response”; Journal of the Royal Statistical Society Series B; 2017; vol 79 (5), pp. 1439-1462 (with S. Chick and M. Forster).</li> </ul>

- “Static and dynamic efficiency of irreversible health care investments under alternative payment rules”; Journal of Health Economics, 2012, vol. 31, n. 1, pp. 169-179 (with R. Levaggi and M. Moretto).

**Reference: 2.1**
**European Initiative: Water4All**

The Water4All Partnership - Water Security for the Planet - is co-funded by the European Union within the frame of the Horizon Europe programme (a key funding programme for research and innovation). The Partnership duration is for seven years from 2022. The objectives are to tackle water challenges as means to face climate change, help to achieve the United Nations’ Sustainable Development Goals and boost the EU’s competitiveness and growth. There are 7 key themes: IV) Water and health. Anti-Microbial Resistance (AMR) is considered an imminent global public health threat.

Member of the SWG:



Name and Surname

**Juliette Arabi**

Organisation

French National Research Agency (ANR)

Brief CV (the entire profile is expected to take up one page)

Juliette Arabi holds a Ph.D. in molecular biology and she has 10+ years’ experience in project management. She is currently international project officer in the “Environment, Ecosystems, and Biological Resources” department at the French National Research Agency (ANR) in Paris. She is trained to work in multidisciplinary and multicultural environments, and to manage multilateral activities. For the past eight years, she has been working in the coordination of the Joint Programming Initiative on “Water challenges for a changing world” - Water JPI. She was also involved in various European projects, including the management of the IC4Water CSA for the development of international cooperation in the water area, and the implementation of additional activities in the scope of several ERA-NETs Cofund, WaterWorks2014, WaterWorks2015, WaterWorks2017 and BiodivRestore. Since June 2022, she works in the coordination team of the Water4All Partnership, a multiannual and multidisciplinary initiative co-financed by the European Commission within the Horizon Europe framework programme. Water4All aims to structure research and innovation in the water sector in Europe and internationally, gathering over 90 partners from 33 countries. Water4All objectives are to tackle water challenges as means to face climate change, help to achieve the UN SDGs and boost the EU competitiveness and growth.

Juliette’s interest for water issues and their interconnection with health started in 2011 when she worked in southern America for the implementation of a ceramic water filter factory in Ecuador. As representative of ANR, funding partner organisation, she took part in the development and follow-up of the Water JPI Knowledge Hub on contaminants of emerging concern.

**Reference: 2.2**

**European Initiative: FutureFoodS**

Food not only supports human life and good health, but also currently has a large social, cultural, environmental and economic dimension. However, the food systems are facing global challenges such as population overgrowth, urbanisation, migration, climate change and resources scarcity. To tackle the effects of these complex social and ecological challenges, we need to innovate in our food systems, to adapt and to prepare them for the future. In addition, Food systems should deliver food security and ensure nutrition security. Providing food and nutrition security (FNS) in the context of a changing world requires urgent political actions, a long-term approaching and civil society commitment. The European R&I (research and innovation) policy plays a crucial role in future proofing food systems, and contributes to achieving the Sustainable Development Goals priority for 2030.

In this sense, the main mission of SCAR FOOD SYSTEMS STRATEGIC WORKING GROUP (SCAR FS SWG) is to provide strategic advice and orientation, and to support the EU R&I policy framework FOOD2030 and its four priorities: NUTRITION for sustainable and healthy diets; CLIMATE smart and environmentally sustainable food systems; CIRCULARITY and resource efficient food systems; INNOVATION and empowerment of communities.

**Member of the SWG:**



**Name and Surname:**

**Gilles Feron**

**Organisation**

French National Research Agency (ANR)

**Brief CV (the entire profile is expected to take up one page)**

Gilles Feron is a research director at INRAE (National Research Institute for Agriculture, Food and the Environment), at the Centre for Taste and Feeding Behaviour (CSGA, Dijon, France), where he has been Deputy Director since 2021. He received a PhD in plant biology & technology from the Institut National Polytechnique (Toulouse, France). His main research topic has always been the investigation of food

flavors metabolism and in particular the identification and regulation of biochemical and enzymatic mechanisms involved in their formation in complex biological systems (from plants to humans). He is currently working on the importance of the oral sphere and saliva in the formation, release and perception of aroma and taste compounds during food consumption. He is conducting his research on specific (children, seniors, obese) and pathological (cancer) populations. He has published more than 140 articles, book chapters and patents. He presented his research at over 120 national and international scientific meetings. He was a member of the scientific committee of the food oral processing conference series on which he was the chairman of the second edition in 2012. He has supervised numerous master students and young researchers. He has been involved in National and European research contracts as the scientific manager as well as the coordinator and in numerous industrial projects.

Since November 2022, Gilles Feron has been involved as a coordinator in building FutureFoodS, the European Sustainable Food Systems Partnership for People, Planet and Climate. In September 2023, he will be hired as a scientific officer at the French National Research Agency (ANR) to ensure the coordination of FutureFoodS.

<b>Reference: 2.3</b>
-----------------------

<b>European Initiative: SBEP</b>
----------------------------------

The Sustainable Blue Economy Partnership is a Horizon Europe co-funded partnership. It constitutes a network of 60 Partner institutions from 25 countries and the European Commission that enables an unprecedented effort to pool research and innovation investments and align national programmes at pan-European scale, taking into consideration the sea-basin (Mediterranean, Black Sea, Baltic and North Sea) and Atlantic Ocean dimension. Intervention areas: 4) Healthy 'Blue Food' under a 'One Health' approach; 5) Enabling the green transitions of 'Blue Food' production
--


Member of the SWG:
--------------------

<b>Receipt of documents is pending (Profile form / Statement of Acceptance)</b>
---

Name and Surname:
-------------------

<b>Maurice Heral</b>
----------------------

<b>Reference: 2.4</b>
<b>European Initiative: FACCE-JPI</b>
In the last years, climate change and food and nutrition security have become high-level priorities in the policy agenda both at national and global levels. The Joint Programming Initiative on Agriculture, Food Security and Climate Change (FACCE-JPI) was launched in 2010, and currently brings together 24 member countries <sup>1</sup> . Its aim is to build the European Research Area (ERA) tackling the challenges at the intersection of agriculture, food security and climate change that cannot be addressed solely at the national level.
Member of the SWG:
<b>Receipt of documents is pending (Profile form / Statement of Acceptance)</b>
Name and Surname:
<b>Heather McKhann</b>

<b>Reference: 2.5</b>
<b>European Initiative: EU Partnership Animal Health and Welfare</b>
The European Partnership Animal Health & Welfare (EUP AH&W) intends to be a Research and Innovation Partnership set up in the context of Horizon Europe. Its general goals are to progress Europe towards healthy and sustainable livestock production systems (for both terrestrial and aquatic animals), including the reduction of anti-microbial usage, and to greatly improve production animal welfare, in line with the European Green Deal and farm-to-fork strategy. Furthermore, the EUP AH&W will enhance public health and well-being by facilitating cross-sector collaboration in a One Health – One Welfare perspective.
Member of the SWG:

Name and Surname
<b>Agnès Roba</b>
Organisation
Fonds de la Recherche Scientifique – FNRS (F.R.S.-FNRS)
Brief CV (the entire profile is expected to take up one page)
-December 2022 - today: Policy Officer at F.R.S.-FNRS – international affairs (Belgium)

- Management of European Partnerships in the field of life sciences and health
- 2017-2022: PhD in Biological Sciences at the University of Namur (Belgium)
- Orientation: Molecular and Medical Microbiology
- Topic: “Histidine biosynthesis, cell separation and copper resistance in the pathogenic bacterium *Brucella abortus*”
- 2017 (5 months): Research Intern at University of California Davis (USA)
- Orientation: Molecular and Medical Microbiology
- 2015-2017: Master’s degree in Biochemistry and Molecular Biology at the University of Namur (Belgium)
- 2012-2015: Bachelor’s degree in Biological Sciences at the University of Namur (Belgium)

**Reference: 2.6**
**European Initiative: NordForsk**

NordForsk is an organisation under the Nordic Council of Ministers that provides funding for and facilitates Nordic cooperation on research and research infrastructure.

Member of the SWG:



Name and Surname


**Kristin Andersen**


Organisation

NordForsk

Brief CV (the entire profile is expected to take up one page)

- February 2023: Special adviser Health and care, NordForsk.org
- September 2019: Special adviser, coordinator and team leader Health and care and welfare systems, The Norwegian Research Council
- June 2015- Senior adviser and NCP for health, delegate in SC1 PC, The Norwegian Research Council
- 2008-2015, Researcher, Institute for Cancer Research, Oslo University Hospital
- 2006-2007, Visiting Postdoc, Lawrence Berkeley Lab, Berkeley, CA, US
- 2005-2006 Postdoc, Institute for Cancer Research, Oslo University Hospital
- 1999-2004 PhD student, Institute for Cancer Research, Oslo University Hospital

<b>Reference: 3.1</b>
<b>European Initiative: ECRIN</b>
<p>ECRIN is a European research infrastructure that facilitates researchers to set up and conduct multinational clinical trials in Europe. We do this by linking with our national European Correspondents, the national networks of clinical trial units, and through our services and tools. ECRIN is based in Paris (France), we work with our 12 member countries across Europe, as well as, additional European or international partners. Our network consists of over 120 clinical trial units, our clinical trial portfolio now counts 70 multinational trials with a mean of 6.3 countries per trial, we have participated in more than 40 international infrastructure development projects, and ECRIN is ISO 9001:2015 certified for its core services.</p>
Member of the SWG:

Name and Surname
<b>Marta del Álamo</b>
Organisation
ECRIN
Brief CV (the entire profile is expected to take up one page)
<p>Marta del Alamo is Project Manager at ECRIN in Paris. She is focused on coordinating ongoing multinational clinical trials in several European countries and providing support to clinical investigators preparing clinical studies/projects for European funding. Marta is also actively involved in ECRIN's capacity building / infrastructure development activities.</p> <p>Previously Marta worked at SCReN, the Spanish Clinical Research Network, as project manager and was a member of the Ethics Committee at Hospital Ramon y Cajal in Madrid. As a previous research scientist in the field of molecular biology and virology, she has worked at Centro de Biología Molecular Severo Ochoa and Centro Nacional de Biotecnología (Spain) and Scripps Research Institute, Washington University in St Louis and Stanford University (USA).</p> <p>Marta received a BA in biology (biotechnology) from Universidad Complutense de Madrid, and a PhD in molecular biology from Universidad Autónoma de Madrid. She also did a post-graduate programme in clinical trials management in Madrid.</p>


<b>Reference: 3.2</b>
<b>European Initiative: EATRIS</b>
<p>EATRIS is the European infrastructure for translational medicine. They bring together resources and services for research communities to translate scientific discoveries into benefits for patients. They are a non-profit organisation that provides access to a vast array of expertise and facilities from 144+ top-tier academic centres across Europe. They focus on improving and optimising preclinical and early clinical development of drugs, vaccines and diagnostics, and overcome barriers to health innovation.</p> <p>Their research infrastructure offers a broad range of research services for both academia and industry across various research fields. In addition, we work with public funding agencies, charities and policy makers with tailored actions to help improve the translational research and innovation ecosystem. The EATRIS community comprises world class facilities providing collaborative services in ATMPs (Advanced Therapeutic Medicinal Products), among other areas.</p>
<b>Member of the SWG:</b>

<b>Name and Surname</b>
<b>Anton Ussi</b>
<b>Organisation</b>
EATRIS ERIC
<b>Brief CV (the entire profile is expected to take up one page)</b>
<p>Anton Ussi (MSc) is Operations &amp; Finance Director at EATRIS ERIC, the ESFRI European landmark infrastructure for translational medicine. Joining EATRIS in 2010, he was part of the team responsible for the design and statutory incorporation of the infrastructure, whose membership counts 14 European Members States. In his current role as CEO since 2015, Ussi has a background in technology transfer focused on molecular imaging, with previous history in mechanical engineering and automotive design, and small business administration. He specialises in public-private and public-public collaboration and translational research in medicine. Ussi is also Principle Investigator of REMEDI4ALL, a large EU-funded initiative to develop a European medicines repurposing framework.</p>



<b>Reference: 3.3</b>
<b>European Initiative: ESFRI</b>
<p>The European Strategy Forum on Research Infrastructures , is a strategic instrument to develop the scientific integration of Europe and to strengthen its international outreach. It was established in 2002, with a mandate from the EU Council to support a coherent and strategy-led approach to policy-making on research infrastructures in Europe, and to facilitate multilateral initiatives leading to the better use and development of research infrastructures, at EU and international level. The mission of ESFRI is to support a coherent and strategy-led approach to policy-making on research infrastructures in Europe, and to facilitate multilateral initiatives leading to the better use and development of research infrastructures, at EU and international level. ESFRI's delegates are nominated by the Research Ministers of the Member and Associate Countries, and include a representative of the Commission, working together to develop a joint vision and a common strategy.</p>
<b>Member of the SWG:</b>

<b>Name and Surname</b>
<b>Dominik Sobczak</b>
<b>Organisation</b>
European Commission, DG Research and Innovation
<b>Brief CV (the entire profile is expected to take up one page)</b>
<p>Dominik Sobczak graduated from Warsaw School of Economics in Finance and Banking and in European Studies, where he also worked as a research project manager and a researcher in macroeconomics, financial markets and European integration. After joining the European Commission in 2005 he worked in the area of socio-economic sciences and humanities in DG Research and Innovation, developing the European research agenda in macroeconomics, finance, demography, corporate social responsibility and youth, among others. In 2014 he joined the Research Infrastructures unit as Executive Secretary of the European Strategy Forum on Research Infrastructures (ESFRI), coordinating the support of the European Commission to the Forum and following up the implementation of the ESFRI Roadmap. Since April 2021 he is Deputy Head of Unit for Research and Innovation Actors and Research Careers, continuing his work on research infrastructure policy. He is Commission representatives in a number of ESFRI working groups, including the Strategy Working Group on Health &amp; Food, which is responsible for research infrastructures in life sciences.</p>

<b>Reference: 3.4</b>
<b>European Initiative: EUHA</b>
The European University Hospital Alliance is formed by leading European university hospitals with demonstrated excellence in healthcare, education and research. The vision of the European University Hospital Alliance (EUHA) is to build a network of sustainable healthcare ecosystems in Europe which achieve the best possible quality of care with the resources available. EUHA's strategic plan for 2021-2023 challenges EUHA to 'Lead by Doing'. In these years EUHA will focus on applying the unique role of academic medicine to improve population health and healthcare outcomes, by leading the development of innovative solutions to the most important challenges facing European health and healthcare. EUHA includes a Clinical Trials Working Group
Member of the SWG:
<b>Receipt of documents is pending (Profile form / Statement of Acceptance)</b>
Name and Surname
<b>Lynn Seveke</b>

<b>Reference: 3.5</b>
<b>European Initiative: conect4children</b>
conect4children, c4c, pan-European paediatric clinical research network is a large collaborative European network that aims to facilitate the development of new drugs and other therapies for the entire paediatric population. It is a pioneering opportunity to build capacity for the implementation of multinational paediatric clinical trials whilst ensuring the needs of babies, children, young people and their families are met. It is committed to meeting the needs of paediatric patients thanks to a novel collaboration between the academic and the private sectors, which includes 35 academic and 10 industry partners and around 500 affiliated partners.
Member of the SWG:

Name and Surname
<b>Mark Turner</b>
Organisation
University of Liverpool
Brief CV (the entire profile is expected to take up one page)
Professor Mark Turner BSc, PhD, MBChB, DRCOG, MRCP(UK), FRCPCH, FFPM(Hon) Professor of Neonatology and Research Delivery, University of Liverpool, UK

Mark Turner graduated from Manchester University with a medical degree in 1991 and a PhD in 1999 (placental physiology). He trained in neonatal medicine in the North West of England and has worked as a Consultant Neonatologist in Liverpool since 2005. His research aims to improve the access of newborn babies and children to high quality medicines. This has included studies of dosing, safety, and efficacy of 15 medicines (contributing to writing 5 paediatric investigation plans); excipient kinetics; manipulations of medicines; the assessment of adverse drug reactions; and the value of age-appropriate formulations. He believes that the coherent integration of the design and conduct of clinical trials is key to improving the quality of medicines. He works to develop efficient medicines research infrastructure in Europe and globally as Chair of the European Network for Paediatric Research at the European Medicines Agency (EnprEMA) (2013 – 2019), co-Director of the International Neonatal Consortium and as co-Coordinator of the Collaborative Network for European Clinical Trials For Children (conect4children, c4c). He is a citizen of the UK and of the Republic of Ireland and Visiting Professor of Paediatrics at University College Cork, Ireland, and the University of Ghent, Belgium.

### Reference: 3.6

#### European Initiative: MIRRI-ERIC

The Microbial Resource Research Infrastructure (MIRRI) is the pan-European distributed Research Infrastructure for the preservation, systematic investigation, provision and valorisation of microbial resources and biodiversity. MIRRI brings together 50+ microbial domain Biological Resource Centres (mBRCs), culture collections and research institutes from ten European countries. MIRRI serves the bioscience and the bioindustry communities by facilitating the access, through a single point, to the broadest range of high-quality microorganisms, their derivatives, associated data and services, with a special focus on the domains of Health & Food, Agro-Food, and Environment & Energy.

Member of the SWG:



Name and Surname

**Luís Miguel Guimarães Soares**

Organisation

Microbial Resource Research Infrastructure - European Research Infrastructure Consortium (MIRRI-ERIC)

Brief CV (the entire profile is expected to take up one page)

Luís Soares is the Executive Director of MIRRI-ERIC, the pan-European distributed Research Infrastructure for the preservation, study, provision and valorisation of microbial resources and biodiversity, with a special focus on the domains of Health & Food, Agro-Food, and Environment & Energy. He represents MIRRI-ERIC in the Life Sciences Research Infrastructure Strategy Board, and in the ERIC Forum. In the past, he has worked for 13 years on cluster and network development, being involved

in conceiving, implementing and consolidating the Health Cluster Portugal (HCP), first as Project Manager, then as Director of Studies and Planning, and finally as Chief Strategy Officer. As appointed/invited expert, he has held several positions in Portuguese and European working groups and networks, namely: Portugal's Delegate to the Health and Food Strategy Working Group, run by the European Strategy Forum on Research Infrastructures (ESFRI); Member of the Portugal in Europe Research and Innovation Network (PERIN); Co-coordinator of the Research & Innovation Agenda on Health and Clinical and Translational Research, run by the Portuguese Foundation for Science and Technology (FCT); Member of the H2020 SC1 Programme Committee, run by the European Commission; Member of the Regional Platform for Smart Specialisation in Life Sciences and Health, and Member of the Norte Regional Innovation Council, run by the Norte Portugal Regional Coordination and Development Commission (CCDR-N); Representative of Portugal in the Board of EATRIS – European Infrastructure for Translational Medicine. in expert panels of European projects, in advisory boards of innovation projects, and in stakeholder panels of projects dedicated to public innovation policies. He also has had numerous participations as Guest Lecturer in post-graduation programmes, and as speaker/moderator in scientific/business events and training programmes. Luís Soares has a Degree in Applied Biology and a PhD in Sciences (Biology), both from the University of Minho.

**Reference: 3.7**
**European Initiative: ERINHA**

ERINHA is a pan-European distributed Research Infrastructure dedicated to the study of high-consequence emerging and re-emerging pathogens. It brings together leading European Bio-Safety Level 4 and complementary (e.g. BSL3) facilities with longstanding experience of research in the field of highly infectious diseases. Such a coordinated approach is vital in a context marked by frequent globalization of infectious diseases with high risk for public health, society and economy. The overarching goal of ERINHA is to provide capacities to conduct projects which are broad in scope, ambition and require a range of capabilities that no single facility or even country can provide on its own.

Member of the SWG:

**Receipt of documents is pending (Profile form / Statement of Acceptance)**

Name and Surname

**Diana Stepanyan**

**Reference: 3.8**
**European Initiative: EOSC**


European Open Science Cloud (EOSC) Partnership aims to deploy and consolidate by 2030 an open, trusted virtual environment to enable the estimated 2 million European researchers to store, share and reuse research data across borders and disciplines.


Member of the SWG:


**Receipt of documents is pending (Profile form / Statement of Acceptance)**

Name and Surname

**Ute Gunsenheimer**

<b>Reference: 3.9</b>
<b>European Initiative: Trials@Home</b>
<p>The Trials@Home consortium explores the opportunities of moving clinical trials from the traditional clinic setting to the participant’s immediate surroundings. These so-called Decentralised Clinical Trials (DCTs) make use of new, digital innovations and enable participants to visit a clinical trial centre less frequently, if at all. Trials@Home follows a co-creative multi-stakeholder approach where academic partners, Small and Medium-sized Enterprises (SMEs), private foundations, and EFPIA partners will work together with other stakeholders from across the medical, technological, regulatory, ethical and social aspects of DCTs, with a common goal to develop concrete and practical recommendations, and pilot tools supporting widespread acceptance and use of DCTs in Europe.</p>
<b>Member of the SWG:</b>

<b>Name and Surname</b>
<b>Mira Zuidgeest</b>
<b>Organisation</b>
University Medical Center Utrecht
<b>Brief CV (the entire profile is expected to take up one page)</b>
<p>Mira Zuidgeest, PhD, PharmD, MSc epidemiology Associate Professor, University Medical Center Utrecht, NL</p> <p>Mira Zuidgeest works as an Associate Professor at the Julius Center for Health Sciences and Primary Care of the University Medical Center Utrecht. Trained both as pharmacist and epidemiologist and with a PhD in pharmacoepidemiology in the field of paediatric asthma, her current work focuses on clinical trial innovation, both methodological and operational. As academic lead for the IMI Trials@Home project (<a href="http://www.trialsathome.com">www.trialsathome.com</a>), she researches possibilities of centring trials around patients rather than clinical sites by use of innovative technologies (Decentralised Clinical Trials). She is board member of the GetReal Institute (<a href="http://www.getreal-institute.org">www.getreal-institute.org</a>) and led the development of a decision-support tool (<a href="http://www.getrealtrialtool.eu">www.getrealtrialtool.eu</a>) for randomised clinical trials integrated into routine clinical practice (pragmatic trials), to understand methodological and operational consequences of introducing real-world elements in trial design. She is also investigating the possibilities of the new CTR category of low-intervention clinical trials.</p>

<b>Reference: 3.10</b>
<b>European Initiative: COMET</b>
<p>The COMET Initiative brings together people interested in the development and application of agreed standardised sets of outcomes, known as ‘core outcome sets’ (COS). These sets represent the minimum that should be measured and reported in all clinical trials of a specific condition, but COS are also suitable for use in routine care, clinical audit and research other than randomised trials. You can read the core outcome set/COMET plain language summary <a href="#">here</a>. The existence or use of a core outcome set does not imply that outcomes in a particular study should be restricted to those in the relevant core outcome set. Rather, there is an expectation that the core outcomes will be collected and reported, making it easier for the results of studies to be compared, contrasted and combined as appropriate; while researchers continue to explore other outcomes as well. COMET aims to collate and stimulate relevant resources, both applied and methodological, to facilitate exchange of ideas and information, and to foster methodological research in this area.</p>
<b>Member of the SWG:</b>

<b>Name and Surname</b>
<b>Paula Williamson</b>
<b>Organisation</b>
University of Liverpool
<b>Brief CV (the entire profile is expected to take up one page)</b>
<p>Paula Williamson is Professor of Biostatistics at the University of Liverpool. Her research programme has focussed on several aspects of evidence-based medicine (EBM) including clinical trials, meta-analysis, health outcome selection, and reducing waste in research. She was appointed as an NIHR Senior Investigator in 2014, gave the Bradford Hill Lecture in 2017, and was elected Fellow of the Academy of Medical Sciences (AMS) in 2018, and to AMS Council in 2021.</p> <p>She chaired the MRC Network of Hubs for Trials Methodology Research, 2008-2018, led a successful bid for a new MRC Trials Methodology Research Partnership from 2019, bringing together major organisations and 25 UK universities. She leads an MRC Doctoral Training Programme in Trials Methodology across 12 Research Organisations.</p> <p>Paula co-founded the global COMET (Core Outcome Measures in Effectiveness Trials) Initiative in 2010, to improve the quality and relevance of health research to decision makers including patients, health professionals, regulators and policymakers. COMET was the winner of the international Cochrane-REWARD prize in 2017 for reducing waste in research. COMET is a finalist in the inaugural 2023 MRC Open Science Impact Prize.</p>

<b>Reference: 3.11</b>
<b>European Initiative: ELIXIR</b>
ELIXIR is a Life-Science Infrastructure for Biological Information that unites Europe’s leading life science organisations in managing and safeguarding the increasing volume of data being generated by publicly funded research. It coordinates, integrates and sustains bioinformatics resources across its member states and enables users in academia and industry to access services that are vital for their research.
Member of the SWG:

Name and Surname
<b>Andrew Smith</b>
Organisation
ELIXIR
Brief CV (the entire profile is expected to take up one page)
<p>Andrew Smith joined ELIXIR in 2011. As Head of External Relations, Andy manages a team responsible for ELIXIR’s communications, industry engagement, international collaboration and socio-economic impact assessment. In addition, Andy is responsible for engagement with existing and prospective Member States of ELIXIR and leads ELIXIR’s engagement with the EU institutions such as the European Commission and other related EU initiatives.</p> <p>Previously he worked in Brussels for the UK Research Office (UKRO), covering various research programme and policy fields, including acting as National Contact Point helpdesks and supporting UK delegations Programme Committees. Prior to this he has held roles in regional government, managing EU Structural Funds, and on education programmes in Slovenia and the Czech Republic.</p>

<b>Reference: 3.12</b>
<b>European Initiative: REMEDI4All</b>
<p>REMED4ALL is an EU-funded research initiative to drive forward the repurposing of medicines in Europe.</p> <p>The platform has the potential to bring down times and costs of drug development by focusing on already approved, discontinued, shelved or investigational therapeutics.</p> <p>The REMED4ALL consortium brings together a unique combination of expertise to address the complexities of drug repurposing. Under the leadership of EATRIS, the European infrastructure for translational medicine, 24 organisations in the fields of clinical and translational research, clinical operations, patient engagement and education, regulatory framework, funding, governance, Health Technology Assessment (HTA) and pricing and reimbursement will closely collaborate to make drug repurposing mainstream.</p>
Member of the SWG:
<b>Receipt of documents is pending (Profile form / Statement of Acceptance)</b>
Name and Surname
<b>Christine Kubiak</b>

#### 4. CONCLUSIONS

The main conclusion reached after the elaboration of this deliverable is that the creation of a SWG with contact persons for each initiative, will provide:

- More accurate information regarding the identification of potential synergies with E4H since the contact persons contacted are involved in the initiative, each of them with different roles (coordinator, partner, manager, stakeholder...).
- The invitation of EC representatives in the field of health and research to the SWG workshops will ensure alignment with the Horizon Europe strategies and Work Programmes.
- The involvement of the contact persons in the official ERA4Health SWG translate the members the importance of collaborating for the annual identification of synergies and their participation in the annual workshop.



- Having the contact details of a contact person for each initiative gives E4H the possibility of reaching them if needed whenever needed during the E4H project execution, for example for exchanging relevant information and establishing ad-hoc collaborations.
- The delivery of the Statement of Acceptance and the Profile Form proves the commitment of the members of the SWG with the initiative of searching potential synergies.
- All the members of the SWG will contribute to disseminate the activities and results of E4H increasing the impact on the Partnership visibility.
- Contacted persons to be involved in the SWG as members expressed gratitude for inviting them to be a member of the SWG and find the identification of synergies and the organisation of a workshop to receive information about other initiatives very interesting and necessary. See below some comments received from some members of the SWG:

*“Thank you very much for this invitation which I am happy to accept. It is indeed of great importance to build the synergies among different Partnerships and the initiative of ERA4Health to create SWG can be only applauded”*

*“What a pleasure to hear from you with such a good initiative! Congratulations on your participation in ERA4Health by leading the task aimed at finding synergies with other EU initiatives, a crucial issue in the field of EU project funding”*

*“Thank you very much for inviting us to join the SWG of the ERA4Health. As coordinators of EU-Africa PerMed we will be very happy to join, as we think that it is important that European initiatives and projects working on health research know what we are each doing, so that we can collaborate and coordinate activities”*

Some difficulties have been found during the creation of the SWG:

- A contact person for all the initiatives was not easy to find or gave not answer to us.
- Some persons contacted showed interest in the initiative but take too much time to send the confirmation of their participation.

The final conclusion got after the creation of this deliverable is that E4H has elaborated a very useful register of initiatives and a SWG which will contribute not only to avoid overlapping and duplicities in the research lines to be funded, but also to initiate very interesting collaborations with those initiatives.

The content of this deliverable will be updated during the whole duration of the Partnership E4H. Contact persons will continue to be sought for those initiatives that do not have an officially assigned member.

## 5. ANNEXES

- ANNEX I: TEMPLATE OF THE STATEMENT OF ACCEPTANCE
- ANNEX II: PROFILE FORM

## **ERA4Health PROJECT**

Fostering a European Research Area for Health

### **Statement of Acceptance - Members of the Synergies Working Group**

E4H is a European Partnership which main aim is to foster a European Research Area for Health Research. IT brings together 33 entities from 22 countries with the common goal of addressing public health needs, ensuring that combined financial resources are used in the most effective and efficient way, best practices are shared, and knowledge is created, disseminated and used for the benefit of all key stakeholders.

The main aim of the SWG is to find synergies among the most relevant EU initiatives related to the health area to avoid overlapping and share knowledge.

#### **The Undersigned:**

Name and Surname: <XXXXXX>  
Institution: <XXXXXX>  
European Initiative: <XXXXXX>  
Role (coordinator, partner, other): <XXXXXX>

#### **Herewith declares as follows:**

1. **XXXXXX** ("Person") has agreed with the Partnership ERA4Health, hereinafter referred to as "E4H", to act as Member of the Synergies Working Group, hereinafter referred to as "SWG".
2. **XXXXXX** ("Person"), with the acceptance of participation in the Synergies Working Group assumes the confidentiality of the shared information and agrees not to use this Confidential Information for purposes other than the proper implementation of the Synergies Working Group of ERA4Health.

And authorises E4H:

1. To include my personal details in the reports that will be prepared for the justification of the project to the European Commission. Only those included in this statement and in the SWG profile sent to E4H.
2. To use the information that I will provide during the activities organized by the SWG to contribute to the identification of synergies and fields of collaboration in the framework of the E4H performance and to be included in the reports that will be sent to the European Commission.
3. To share with all the partners of E4H the information that I will provide during the activities organized by the SWG.
4. To send me information about future activities related to E4H.





Signature \_\_\_\_\_

Name \_\_\_\_\_

Date \_\_\_\_\_

In accordance with the provisions of Regulation (EU) 2016/679 of the European Parliament and of the Council, of 27 April 2016, on the protection of natural persons with regard to the processing of personal data and on the free movement of such data, you are informed that your personal data provided will only be kept for as long as necessary to fulfill the purpose for which they were collected and to determine the possible responsibilities that could be derived from said purpose and data processing.



**Funded by  
the European Union**

The project "Fostering a European Research Area for Health (ERA4Health)" has received funding by the European Commission under GA 101095426

